Related Articles Long term Overall Survival Outcomes in Patients with Early Stage Peripherally Located Non small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non academic Cancer Centre Clin Oncol R Coll Radiol 2020 Dec 16 Authors Wood A Aynsley E Kumar G Masinghe S Anderson M Veeratterapillay J Huntley C Blower A Green J Johnson D Daniel J Curtis H Reynolds J Turnbull M Harland K Swingler A Banham E Burke K Bradley J Greenhalgh A Peedell C Abstract AIMS To report long term outcomes of patients treated with stereotactic ablative radiotherapy SABR for early stage peripherally located non small cell lung cancer MATERIALS AND METHODS Data were collected retrospectively between September 2009 and May 2019 Electronic medical records were reviewed for baseline characteristics treatment details and outcomes All patients were treated according to local protocol based on the national UK SABR Consortium guidelines Risk adapted treatment schedules were used depending on the size and the location of the tumour 54 Gy in three fractions 55 Gy in five fractions 60 Gy in eight fractions or 50 Gy in 10 fractions Overall survival outcomes were evaluated using the Kaplan Meier method RESULTS In total 412 patients were included in the analysis The median age was 76 years range 48 93 years Histological confirmation was obtained in 233 cases 56 6 The median overall survival for all patients was 42 3 months 95 confidence interval 37 3 47 3 months with 3 and 5 year overall survival of 52 8 and 37 3 respectively For biopsy proven patients 56 6 3 and 5 year overall survival was 57 3 and 40 1 respectively With respect to overall survival univariate and multivariate analysis revealed no significant difference in survival by technique volume modulated arc therapy versus conformal three dimensional computed tomography versus four dimensional computed tomography tumour location smoking status at first contact pre treatment tumour stage or pre treatment standardised uptake value Survival was poorer for patients who received the 50 Gy in 10 fractions schedule Treatment was very well tolerated with very low rates of grade 3 4 toxicity 1 CONCLUSIONS SABR for peripherally located medically inoperable non small cell lung cancer can be safely and effectively implemented in a non academic institution with appropriate equipment and training Overall survival outcomes and toxicity rates are comparable with internationally published studies Patients treated with 50 Gy in 10 fractions had a poorer survival outcome PMID 33341333 PubMed as supplied by publisher